Investing.com - Biotricity reported on Friday second quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Biotricity announced earnings per share of $-0.09 on revenue of $2.38M. Analysts polled by Investing.com anticipated EPS of $-0.08 on revenue of $2.54M.
Biotricity shares are down 71% from the beginning of the year , still down 78.87% from its 52 week high of $5.30 set on Tuesday, December 28, 2021.
Biotricity follows other major Healthcare sector earnings this month
Biotricity's report follows an earnings beat by Eli Lilly on Tuesday, November 1, 2022, who reported EPS of $1.98 on revenue of $6.94B, compared to forecasts EPS of $1.91 on revenue of $6.91B.
Pfizer had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.78 on revenue of $22.6B, compared to forecast for EPS of $1.44 on revenue of $21.33B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar